Postpartum thyroiditis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Usama Talib (talk | contribs) No edit summary |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
{{Postpartum thyroiditis}} | {{Postpartum thyroiditis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SKA}} | ||
==Overview== | ==Overview== | ||
According to the American Journal of Obstetrics and Gynecology, screening for [[postpartum thyroiditis]], done by measuring anti-[[Thyroid peroxidase|TPO]] [[antibodies]] is recommended for every pregnant woman. According to the Endocrinology and Metabolism Clinics of North America, screening for [[postpartum thyroiditis]] in first trimester, by measuring anti-[[Thyroid peroxidase|TPO]] [[antibodies]], should be limited to every high-risk pregnant women with [[Diabetes mellitus type 1|type 1 DM]] and history of [[postpartum thyroiditis]]. According to these recommendations, any patient with high risk of PPT should be followed with [[Thyroid-stimulating hormone|TSH]] levels in every 6th and 9th postpartum month. | |||
==Screening== | ==Screening== | ||
*According to the American Journal of Obstetrics and Gynecology screening for [[postpartum thyroiditis]] by measuring anti-[[Thyroid peroxidase|TPO]] [[antibodies]] is recommended every pregnant women.<ref name="pmid3394739">{{cite journal| author=Hayslip CC, Fein HG, O'Donnell VM, Friedman DS, Klein TA, Smallridge RC| title=The value of serum antimicrosomal antibody testing in screening for symptomatic postpartum thyroid dysfunction. | journal=Am J Obstet Gynecol | year= 1988 | volume= 159 | issue= 1 | pages= 203-9 | pmid=3394739 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3394739 }} </ref> | |||
*According to the | *According to the Endocrinology and Metabolism Clinics of North America screening for [[postpartum thyroiditis]] in first trimester by measuring anti-[[Thyroid peroxidase|TPO]] [[antibodies]] should be limited to every high risk pregnant women with:<ref name="pmid10874538">{{cite journal| author=Stagnaro-Green A| title=Recognizing, understanding, and treating postpartum thyroiditis. | journal=Endocrinol Metab Clin North Am | year= 2000 | volume= 29 | issue= 2 | pages= 417-30, ix | pmid=10874538 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10874538 }} </ref> | ||
*According to the Endocrinology and Metabolism Clinics of North America screening for postpartum thyroiditis in first trimester by measuring anti-TPO antibodies should be limited to every high risk pregnant women with: <ref name="pmid10874538">{{cite journal| author=Stagnaro-Green A| title=Recognizing, understanding, and treating postpartum thyroiditis. | journal=Endocrinol Metab Clin North Am | year= 2000 | volume= 29 | issue= 2 | pages= 417-30, ix | pmid=10874538 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10874538 }} </ref> | **[[Type 1 diabetes|Type 1 DM]] | ||
**[[Type 1 DM]] | **History of [[postpartum thyroiditis]] | ||
**History of [[postpartum thyroiditis]] | Any patient with high risk of PPT should be followed with [[Thyroid-stimulating hormone|TSH]] levels in every 6th and 9th postpartum month.<ref name="pmid27579088">{{cite journal| author=Keely EJ| title=Postpartum thyroiditis: an autoimmune thyroid disorder which predicts future thyroid health. | journal=Obstet Med | year= 2011 | volume= 4 | issue= 1 | pages= 7-11 | pmid=27579088 | doi=10.1258/om.2010.100041 | pmc=4989649 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27579088 }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 15:03, 10 November 2017
|
Postpartum thyroiditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Postpartum thyroiditis screening On the Web |
|
American Roentgen Ray Society Images of Postpartum thyroiditis screening |
|
Risk calculators and risk factors for Postpartum thyroiditis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]
Overview
According to the American Journal of Obstetrics and Gynecology, screening for postpartum thyroiditis, done by measuring anti-TPO antibodies is recommended for every pregnant woman. According to the Endocrinology and Metabolism Clinics of North America, screening for postpartum thyroiditis in first trimester, by measuring anti-TPO antibodies, should be limited to every high-risk pregnant women with type 1 DM and history of postpartum thyroiditis. According to these recommendations, any patient with high risk of PPT should be followed with TSH levels in every 6th and 9th postpartum month.
Screening
- According to the American Journal of Obstetrics and Gynecology screening for postpartum thyroiditis by measuring anti-TPO antibodies is recommended every pregnant women.[1]
- According to the Endocrinology and Metabolism Clinics of North America screening for postpartum thyroiditis in first trimester by measuring anti-TPO antibodies should be limited to every high risk pregnant women with:[2]
- Type 1 DM
- History of postpartum thyroiditis
Any patient with high risk of PPT should be followed with TSH levels in every 6th and 9th postpartum month.[3]
References
- ↑ Hayslip CC, Fein HG, O'Donnell VM, Friedman DS, Klein TA, Smallridge RC (1988). "The value of serum antimicrosomal antibody testing in screening for symptomatic postpartum thyroid dysfunction". Am J Obstet Gynecol. 159 (1): 203–9. PMID 3394739.
- ↑ Stagnaro-Green A (2000). "Recognizing, understanding, and treating postpartum thyroiditis". Endocrinol Metab Clin North Am. 29 (2): 417–30, ix. PMID 10874538.
- ↑ Keely EJ (2011). "Postpartum thyroiditis: an autoimmune thyroid disorder which predicts future thyroid health". Obstet Med. 4 (1): 7–11. doi:10.1258/om.2010.100041. PMC 4989649. PMID 27579088.